51 results about "Transforming growth factor beta" patented technology

The present disclosure relates to T cells engineered to comprise a heterologous nucleic acid sequence encoding a dual mutant transforming growth factor beta 1 (dmTGFB1) under control of a promoter sequence and a modification, e.g., knockdown, of an endogenous nucleic acid sequence encoding a TGFBR2. In certain embodiments, the cells further comprise a modification, e.g., knockdown, of an endogenous nucleic acid sequence encoding a TNFA; a modification, e.g., knockdown, of an endogenous nucleic acid sequence encoding an IFNG; and insertion of sequence(s) encoding a regulatory T cell promoting molecule, and compositions and uses thereof.

The present invention relates, in general, to polypeptides capable of binding and neutralizing transforming growth factor beta (TGF-beta) ligands, and uses of these polypeptides for treating disorders related to TGF-beta expression or activation (e.g. cancer and fibrotic diseases), and methods of making such molecules.

The present disclosure provides a polypeptide complex comprising a target binding polypeptide that binds to a molecule on a target cell or a molecule in an extracellular matrix (ECM); and small latent complexes comprising in particular a dimer latent related polypeptide (LAP) or a fragment or derivative thereof, and a dimer mature transforming growth factor beta (TGF beta) family polypeptide or a fragment or derivative thereof. Polypeptides (e.g., fusion polypeptides), and related polynucleotides, vectors, cells, and pharmaceutical compositions are also provided. Also provided are methods of treating subjects using, for example, these polypeptide complexes and / or these fusion polypeptides or pharmaceutical compositions thereof.

The application discloses an electrochemical sensor for detecting IBD protein markers and a preparation method thereof. The electrochemical sensor is composed of a CNT-embedded semi-cured PDMS flexible substrate, deposited gold nanoparticles and a nucleic acid sensing layer. The nucleic acid sensing layer comprises a tumor necrosis factor-alpha sensor, an interleukin 6 sensor, an interleukin 8 sensor, a transforming growth factor beta 1 sensor, a reference electrode and a counter electrode. The tumor necrosis factor-alpha sensor, the interleukin 6 sensor, the interleukin 8 sensor and the transforming growth factor beta 1 sensor all adopt single-stranded aptamers modified by a signal molecule methylene blue, and the nucleotide sequences corresponding to the single-stranded aptamers are SEQ ID NO. 1-4. The application can improve the modulus matching of the sensor and human tissue and excellent biocompatibility, realize accurate detection of low-concentration biomarkers and stable signal output of the sensor under a strain working condition.

The present invention refers to molecules targeting membrane associated latent-transforming growth factor beta-binding protein 2 (LTBP2). Further the invention relates to molecules targeting LTBP2 for treatment and diagnosis of diseases associated with LTBP2 expressing fibroblasts. In particular, the invention refers to a nucleic acid encoding molecule targeting LTBP2 and a cell expressing the molecule targeting LTBP2.

The invention is concerned with a fusion protein comprising interleukin 13 and a regulatory cytokine, for example, an interleukin chosen from interleukin 4, interleukin 10, interleukin 27, interleukin 33, transforming growth factor beta 1, transforming growth factor beta 2, and interleukin 13, a nucleic acid molecule encoding such fusion protein, a vector comprising such nucleic acid molecule, and a host cell comprising such nucleic acid molecule or such vector. The invention further pertains to a method for producing such fusion protein. The fusion protein or a gene therapy vector encoding the fusion protein may be used in the prevention or treatment of a condition characterized by pathological pain, chronic pain, neuro-inflammation and / or or neurodegeneration.

This invention relates to pharmaceutical compositions and methods for treatment of ophthalmic or ocular diseases and conditions. The compositions contain targeting molecules that are made up of a bifunctional hepatoma-derived growth factor-specific antibody covalently attached to a trapper that specifically binds vascular endothelial growth factor and / or transforming growth factor beta. Specific eye conditions that can be beneficially affected by the compositions and methods of the invention include age-related macular degeneration, diabetic retinopathy, peripheral vitreoretinopathy, and retinal vein occlusion.

Certain emboidments provide a method of promoting regeneration of one or more intestinal stem cells in a mammalian organoid culture, the method comprising treating the organoid culture with an effective amount of transforming growth factor beta (TGFB). Certain embodiments also provide a method for preparing an organoid culture comprising intestinal stem cells and a method of treating a subject with damaged or defective intestinal tissue comprising engrafting an organoid into the subject.

The invention is concerned with a fusion protein comprising interleukin 13 and a regulatory cytokine, for example, an interleukin chosen from interleukin 4, interleukin 10, interleukin 27, interleukin 33, transforming growth factor beta 1, transforming growth factor beta 2, and interleukin 13, a nucleic acid molecule encoding such fusion protein, a vector comprising such nucleic acid molecule, and a host cell comprising such nucleic acid molecule or such vector. 5 The invention further pertains to a method for producing such fusion protein. The fusion protein or a gene therapy vector encoding the fusion protein may be used in the prevention or treatment of a condition characterized by pathological pain, chronic pain, neuro-inflammation and / or or neurodegeneration. 20 26 21 41 00 10 A ug 2 02 6 1 0 A u g 2 0 2 6 2 0 2 6 2 1 4 1 0 0

To provide polypeptides capable of not only neutralizing TGF-β but also specifically triggering T cell activation in the presence of TGF-β when expressed in a cell.SOLUTION: The disclosure provides such a peptide comprising a signal peptide, an antigen binding domain comprising a heavy chain variable (VH) region and a light chain variable (VL) region, a peptide spacer, a transmembrane domain and an endodomain, where the antigen binding domain specifically binds to TGF-β. T-cell activation spurs the immune cell to produce immunostimulatory cytokines and proliferate, thus turning TGF-β from an immunosuppressive signal to an activating stimulus.SELECTED DRAWING: None

To provide Transforming Growth Factor Beta (TGF-β) polypeptide constructs and complexes that find use in therapeutic treatment of diseases including autoimmune diseases, nucleic acids that encode the constructs and the complexes, and methods for preparing the constructs and complexes in cell-based expression systems.SOLUTION: A "masked TGF-β construct" includes: (i) a scaffold polypeptide sequence; (ii) a TGF-β polypeptide sequence; (iii) a masking polypeptide sequence optionally including a TGF-β receptor polypeptide sequence or an anti-TGF-β polypeptide sequence; (iv) optionally, one or more independently selected MOD polypeptide sequences; and (v) optionally, one or more independently selected linker polypeptide sequences, as a first polypeptide, wherein the masking polypeptide sequence and the TGF-β polypeptide sequence bond with each other.SELECTED DRAWING: Figure 1

A method and system are disclosed for differentiating non-human primate induced pluripotent stem cells (NHP iPSCs) into hepatocyte-like cells through a defined, multi-stage protocol. The method includes sequentially exposing NHP iPSCs to six distinct cell differentiation media over an approximate eighteen-day period. Each medium comprises defined combinations of growth factors, small molecules, and inhibitors that direct progressive lineage specification through anterior primitive streak, definitive endoderm, posterior foregut, liver bud progenitors, hepatoblasts, and hepatocyte-like cells. Concentration ranges and exposure durations are provided for each stage, ensuring reproducibility and reducing heterogeneity across cell populations. In some embodiments, treatment with a transforming growth factor beta (TGF-β ) receptor I inhibitor during early hepatoblast specification enhances lineage fidelity. The resulting hepatocyte-like cells are validated by immunostaining and western blotting for hepatic markers. Applications include preclinical drug metabolism, hepatotoxicity assessment, and in vitro disease modeling using non-human primate–derived systems.

The invention discloses an intervertebral disc annulus fibrosus repairing material, a scaffold and application of the intervertebral disc annulus fibrosus repairing material and the scaffold. The intervertebral disc annulus fibrosus repairing material comprises magnesium-silicon nanofibers, tannic acid (TA) and transforming growth factor beta (TGF-beta), and the magnesium-silicon nanofibers comprise self-assembled magnesium-silicon-oxygen nanosheets; the magnesium-silicon-oxygen nanosheet is wrapped by tannic acid; the TGF-beta is connected to the tannic acid through a reversible chemical bond. According to the present invention, the immune microenvironment is adjusted so as to enhance the extracellular matrix (ECM) expression of fibrous ring stem cells (AFSCs);

The invention relates to the technical field of biological pharmacy, and discloses a mesenchymal stem cell exosome enhancer and a preparation method thereof, the enhancer is composed of purified mesenchymal stem cell exosome, a functional lipid complex, cytokine sustained release microspheres, a targeting modifier, a stabilizer and a penetration enhancer according to specific parts by weight. The preparation method comprises the following steps: obtaining a high-activity exosome by combining ultracentrifugation with size exclusion chromatography purification; preparing a functional lipid complex composed of cholesterol, sphingomyelin and phosphatidylserine to promote membrane fusion; preparing a sodium alginate-chitosan sustained release microsphere loaded with a basic fibroblast growth factor and a transforming growth factor-beta1; synthesizing an RGD peptide modified hyaluronic acid targeting modifier; and finally, mixing the components, filtering and sub-packaging. The quality fluctuation risk of subsequent preparation preparation is reduced, and it is guaranteed that the final reinforcing agent product has a highly uniform structure.

Recombinant proteins that specifically bind TGFβ are disclosed. The recombinant proteins include a transforming growth factor beta (TGFβ) binding domain and an antibody Fc fragment. Also disclosed are compositions that include the disclosed recombinant protein, and methods of using such compositions for detecting TGFβ in a subject.

The invention is concerned with a fusion protein comprising interleukin 13 and a regulatory cytokine, for example, an interleukin chosen from interleukin 4, interleukin 10, interleukin 27, interleukin 33, transforming growth factor beta 1, transforming growth factor beta 2, and interleukin 13, a nucleic acid molecule encoding such fusion protein, a vector comprising such nucleic acid molecule, and a host cell comprising such nucleic acid molecule or such vector. The invention further pertains to a method for producing such fusion protein. The fusion protein or a gene therapy vector encoding the fusion protein may be used in the prevention or treatment of a condition characterized by pathological pain, chronic pain, neuro-inflammation and / or or neurodegeneration.

This disclosure relates to treating internal disc disruption or a connective tissue injury. The treatment involves injecting, or otherwise administering, a therapeutic composition into an animal, such as a human being, in need thereof. The therapeutic composition may contain transforming growth factor beta 1 (TGF-β1) or transforming growth factor beta 2 (TGF-β2), fibroblast growth factor (FGF), and a pharmaceutically acceptable excipient or a secondary agent.

To provide pharmaceutical compositions for osteoarthritis treatment, comprising immune-tolerized fetal stem cell-derived extracellular vesicles containing various components that promote hyaline cartilage regeneration and relieve inflammation at higher levels than those stem cell-derived extracellular vesicles obtained under general culture conditions, and thus exhibiting superior hyaline cartilage regeneration and anti-inflammatory efficacy as well as methods for manufacturing the extracellular vesicles and compositions for osteoarthritis treatment using the extracellular vesicles.SOLUTION: These extracellular vesicles derived from immune-tolerized fetal stem cells contain fibroblast growth factor-2 (FGF-2), fibroblast growth factor-7 (FGF-7), insulin-like growth factor-1 (IGF-1), transforming growth factor-beta 1 (TGF-β1), bone morphogenetic protein-4 (BMP-4), bone morphogenetic protein-5 (BMP-5), and bone morphogenetic protein-7 (BMP-7) and HLA-G protein.SELECTED DRAWING: Figure 1

A 5 / 6-5 / 6 diaryl compound that inhibits transforming growth factor beta-activated kinase (TAK1); compositions comprising the same compounds; and their use in the treatment of cancer and inflammatory diseases.

Provided are novel serum-free culture media which comprise basic fibroblast growth factor (bFGF), transforming growth factor beta-3 and ascorbic acid at a concentration of at least about 50 microgram / ml; ascorbic acid at a concentration range of about 400-600 microgram / ml, bFGF at a concentration range of about 50-200 ng / ml, xeno-free serum replacement and a lipid mixture; the IL6RIL6 chimera at a concentration range of about 50-200 picogram per milliliter (pg / ml); or leukemia inhibitory factor (LIF) at a concentration of at least 2000 units / ml; cell cultures comprising same with pluripotent stem cells such as human embryonic stem cells and induced pluripotent stem (iPS) cells, and methods of using same for expanding pluripotent stem cells in an undifferentiated state using two-dimensional or three-dimensional culture systems; and methods of expanding iPS cells in a suspension culture devoid of substrate adherence and cell encapsulation.

The application discloses a lignan compound and a preparation method and application thereof, and relates to the technical field of medicines. The application specifically relates to four lignan small-molecule compounds with the same planar structure, which are separated from amber, and include two pairs of enantiomers (+)-6 / (-)-6 and (+)-7 / (-)-7. The compound structures are as follows: In a renal fibrosis model experiment, the lignan compound provided by the application can inhibit the expression of proteins related to renal fibrosis, such as alphaSMA protein, type I collagen protein and fibronectin, in NRK-52E cells induced by transforming growth factor beta 1, which indicates that the lignan compound provided by the application has the use of preparing medicines for preventing and treating renal fibrosis.

This disclosure relates to treating a connective tissue injury. The treatment involves injecting, or otherwise administering, a therapeutic composition into an animal, such as a human being, in need thereof. The therapeutic composition may contain transforming growth factor beta 1 (TGF-β1) and / or transforming growth factor β2 (TGF-β2), connective tissue growth factor (CTGF), and a pharmaceutically acceptable excipient or a secondary agent.

A method for expanding a population of gamma delta T-cells is provided, wherein isolated activated peripheral blood mononuclear cells (PBMCs) are cultured in a medium comprising transforming growth factor beta (TGF-beta) under conditions favoring the production of effector gamma delta T-cells having therapeutic activity against a malignant disease. The use of TGF-beta in the production of effector cells, in particular Vgamma9Vdelta2 T-cells, is also described and claimed.

The invention belongs to the technical field of chemical material engineering, and particularly relates to a hydrogel coating capable of promoting tissue repair and regeneration, which is characterized by being mainly prepared from the following materials: biomolecules mixed in a hydrogel material, and a water-retaining agent, the biomolecules comprise a combination of more than one of the following components: bone morphogenetic protein 7, hepatocyte growth factors, transforming growth factors-beta and retinoic acid. The hydrogel is combined with the carboxylated chitosan hydrogel coating, the bone morphogenetic protein 7 (BMP7), the hepatocyte growth factor (HGF), the transforming growth factor beta (TGF-beta) and the retinoic acid, so that the hydrogel has a synergistic effect of promoting the regeneration and repair of postoperative tissues, and can be applied to the drainage tube to improve the mechanical property and the structural stability and improve the treatment effect.

The invention discloses an electrochemical sensor for IBD protein marker detection as well as a preparation method and application of the electrochemical sensor. The electrochemical sensor is composed of a semi-cured PDMS flexible substrate in which CNT is embedded, deposited gold nanoparticles and a nucleic acid sensing layer, the nucleic acid sensing layer comprises a tumor necrosis factor-alpha sensor, an interleukin 6 sensor, an interleukin 8 sensor, a transforming growth factor beta1 sensor, a reference electrode and a counter electrode; the tumor necrosis factor-alpha sensor, the interleukin 6 sensor, the interleukin 8 sensor and the transforming growth factor beta1 sensor all adopt aptamer single chains modified by signal molecule methylene blue, and correspondingly adopt nucleotide sequences shown in SEQ ID NO.1-4. Matching and excellent biocompatibility of the sensor and human tissue modulus can be improved, and accurate detection of low-concentration biomarkers and stable signal output of the sensor under the strain working condition are achieved.

This disclosure relates to treating a connective tissue injury. The treatment involves injecting, or otherwise administering, a therapeutic composition into an animal, such as a human being, in need thereof. The therapeutic composition may contain transforming growth factor beta 1 (TGF-β1) and / or transforming growth factor β 2 (TGF-β2), connective tissue growth factor (CTGF), and a pharmaceutically acceptable excipient or a secondary agent.

This invention relates to a fusion protein that specifically binds to the extradomain B of fibronectin (EDB-FN) and transforming growth factor β (TGFβ), and its uses. More specifically, it relates to a fusion protein comprising a polypeptide that specifically binds to EDB-FN and a polypeptide that specifically binds to TGFβ, and its uses. The fusion protein of this invention achieves direct localization of TGFβ inhibition within the tumor microenvironment by immobilizing TGFβ, which is important for anti-tumor immune responses, in the extracellular matrix, ensuring local rather than systemic action. It not only exhibits excellent anti-tumor effects in various cancer types, but also, due to the rigidity of the extracellular matrix, demonstrates excellent anti-tumor effects in pancreatic cancer, where traditional TGFβ inhibitors are ineffective. Therefore, it can be usefully applied to the prevention or treatment of cancer.

The present invention relates to compositions, systems, and methods for treating a subject with an eye condition (e.g., topically) using a composition comprising an ACE-2 receptor antagonist (also known as Angiotensin II Receptor Blocker or “ARB”) (e.g., losartan, telmisartan, valsartan, olmesartan, candesartan, irbesartan, eprosartan, azilsartan, or losartan metabolite EXP3174). In certain embodiments, the eye condition is selected from: i) a corneal scarring fibrosis, ii) a transforming growth factor beta-induced (TGFBI) corneal dystrophy, iii) a conjunctival fibrotic disease, iv) an intraocular fibrotic disease, and v) a conjunctival bleb scarring and / or shunt encapsulation (e.g., following glaucoma surgery).

This disclosure relates to treating a connective tissue injury. The treatment involves injecting, or otherwise administering, a therapeutic composition into an animal, such as a human being, in need thereof. The therapeutic composition may contain transforming growth factor beta 1 (TGF-β1) and / or transforming growth factor β 2 (TGF-β2), connective tissue growth factor (CTGF), and a pharmaceutically acceptable excipient or a secondary agent.

Aspects of the disclosure relate to polypeptides comprising a signal peptide, an antigen binding domain that specifically binds to a TGF-β, a spacer peptide, a transmembrane domain, and an endodomain. When expressed in a cell, they are capable of not only neutralizing TGF-β but also specifically triggering T-cell activation in the presence of TGF-β. T-cell activation induces the immune cell to produce immunostimulatory cytokines and to proliferate, thereby converting TGF-β from an immunosuppressive signal to an activating stimulus.